ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSelling/general/admin expenses6.2 M5.23 M3.63 M4.05 M3.77 M16.68 MResearch & development9.37 M4.3 M3.66 M2.83 M6.71 M17.5 MOperating income-15.57 M-9.54 M-7.29 M-6.87 M-78.56 M-102.27 MNon-Operating Income, Total563 K393 K325 K263 K255 K1.24 MInterest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses000000Unusual income/expense563 K393 K325 K263 K255 K1.24 MPretax income-96.94 M-9.14 M-6.97 M-6.61 M-105.61 M-128.33 MEquity in earnings——————Taxes————-2.67 M—Non-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations-15 M-9.14 M-6.97 M-6.61 M-82.89 M-105.61 MDiscontinued operations——————Net income-15 M-9.14 M-6.97 M-6.61 M-82.89 M-105.61 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders-15 M-9.14 M-6.97 M-6.61 M-82.89 M-105.61 MBasic earnings per share (Basic EPS)-3.84-2.3-1.8-1.68-18.92-24.7Diluted earnings per share (Diluted EPS)-3.84-2.3-1.8-1.68-18.92-24.7Average basic shares outstanding3.85 M3.9 M3.91 M3.94 M4.28 M16.03 MDiluted shares outstanding3.85 M3.9 M3.91 M3.94 M4.28 M16.03 MEBITDA-15.27 M—————EBIT-15.57 M—————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)301 K178 K73 K130 K262 K643 K
LeonaBio Inc
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer.